AB Science delays 2023 annual report publication

AB Science, a French pharmaceutical company listed on Euronext Paris, has announced a slight delay in the release of its 2023 annual financial report. Originally scheduled for April 30, 2024, the publication has been postponed to ensure auditors have adequate time to complete their review. The new release date for the financial report is set for no later than May 15, 2024, after trading hours.

Founded in 2001, AB Science specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs). These are targeted proteins crucial for cell signaling pathways. The company's research primarily focuses on diseases with significant unmet medical needs, including those that are often lethal or resistant to previous treatments.

AB Science has developed a proprietary portfolio of molecules, with its leading compound, masitinib, already registered for veterinary use. Masitinib is also being developed for human medical applications in the fields of oncology, neurological diseases, inflammatory conditions, and viral infections. The company operates from its headquarters in Paris, France.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!